Clinical Trial

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-23; most recent amendment 2025-04-18.
Status change: Not Yet Recruiting → Recruiting 2025-04-18
Trial Details
NCT Number NCT05637879
Lead Sponsor White River Junction Veterans Affairs Medical Center
Conditions PTSD
Enrollment 92 participants
Start Date 2023-12-18
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-24